SEARCH

SEARCH BY CITATION

References

  • 1
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 2
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al., and the International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 3
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 645652.
  • 4
    Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5: 124129.
  • 5
    McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 10611069.
  • 6
    Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004; 11: 243250.
  • 7
    McHutchison JG, Manns MP, Longo DL. Definition and management of anemia in patients infected with hepatitis C virus. Liver Int 2006; 26: 389398.
  • 8
    Sulkowski MS. Management of the hematologic complications of hepatitis C therapy. Clin Liver Dis 2005; 9: 601616.
  • 9
    Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. HEPATOLOGY 2007; 45: 806816.
  • 10
    Liu WL, Su WC, Cheng CW, Hwang LH, Wang CC, Chen HL, et al. Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus. J Infect Dis 2007; 196: 425434.
  • 11
    Homma M, Matsuzaki Y, Inoue Y, Shibata M, Mitamura K, Tanaka N, et al. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol 2004; 2: 337339.
  • 12
    Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem 2006; 13: 33513357.
  • 13
    Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 2005; 39 (1 Suppl. ): S3S8.
  • 14
    Wu JZ, Lin CC, Hong Z. Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design. J Antimicrob Chemother 2003; 52: 543546.
  • 15
    Lin C-C, Philips L, Xu C, Yeh L-T. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J Clin Pharmacol 2004; 44: 265275.
  • 16
    Lin CC, Lourenco D, Xu G, Yeh LT. Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver. Antimicrob Agents Chemother 2004; 48: 18721875.
  • 17
    Gish RG, Arora S, Reddy KR, Nelson DR, O'Brien C, Xu Y, et al. Virological response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol 2007; 47: 5159.
  • 18
    Pockros PJ, Jacobson IM, Bacon BR, Afdhal NH, Poordad F, Chun E, et al. Taribavirin exposure analysis from a previous phase III trial correlates with phase IIb weight-based dosing interim results [Abstract]. HEPATOLOGY 2008; 48: 1138A.
  • 19
    Benhamou Y, Pockros P, Rodriguez-Torres M, Gordon S, Shiffman M, Lurie Y, et al. The safety and efficacy of viramidine plus pegylated interferon alfa-2b versus ribavirin plus pegylated interferon alfa-2b in therapy-naïve patients infected with HCV: phase 3 results (VISER1) [Abstract]. J Hepatol 2006; 44(Suppl 2): S273.
  • 20
    Levin J. Viramidine phase III study-did not meet efficacy endpoint. Valeant looking at weight-based dosing of viramidine based on post-hoc analysis [NATAP conference report on Benhamou et al., J Hepatol 2006;44(Suppl 2):S293.]. http://www.natap.org/2006/EASL/EASL_19.htm. Accessed May 2009.
  • 21
    Pockros P, Rodriguez-Torres M, Lurie Y, Gordon S, Shiffman M, Li Y, et al. Impact of taribavirin exposure on efficacy, anemia rates, and GI side effects when used with pegylated interferon alfa-2b for the treatment of chronic hepatitis C [Abstract]. J Hepatol 2007; 46(Suppl): S239.
  • 22
    Jacobson I, Pockros P, Benhamou Y, Esteban-Mur R, Lurie Y, Flisiak R, et al. Impact of taribavirin and ribavirin exposure on efficacy and anemia rates when combined with pegylated interferon alfa-2b in the treatment of chronic HCV [Abstract]. HEPATOLOGY 2006; 44: 610A.
  • 23
    Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. HEPATOLOGY 2007; 46: 971981.
  • 24
    Benhamou Y. Anemia and clinical outcomes in hepatitis C. J Hepatol 2007; 47: 79.
  • 25
    Valeant Pharmaceuticals reports encouraging phase IIb results at treatment week 12 for taribavirin [press release]. Aliso Viejo, CA: Valeant Pharmaceuticals; updated March 17, 2008. http://www.valeant.com/mediaCenter/newsArticle/newsArticle.jspf?objectId=4233. Accessed May 2009.
  • 26
    Pawlotsky J-M, Gish RG. Future therapies for hepatitis C. Antivir Ther 2006; 11: 397408.
  • 27
    Keeffe EB. Future treatment of chronic hepatitis C. Antivir Ther 2007; 12: 10151025.
  • 28
    Pockros PJ. Emerging therapies for chronic hepatitis C virus. Gastroenterol Hepatol 2008; 4: 729734.
  • 29
    McHutchison JG, Everson GT, Gordon SC, Jacobson I, Kauffman R, McNair L, et al. PROVE1: results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C [Abstract]. J Hepatol 2008; 48(Suppl 2): S4.
  • 30
    Kwo P, Lawitz E, McCone J, Schiff EG, Vierling J, Pound D, et al. Interim results from HCV SPRINT-1: RVR/EVR from phase 2 study of boceprevir plus PegIntron™ (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 CHC [Abstract]. J Hepatol 2008; 48(Suppl 2): S372.